Original document(7 pages) Authorized document(7 pages) 中文版
    The Chinese medicine preparation has recipe comprising red sage, astragalus root, epimedium, cordalis tuber and other Chinese medicinal materials. It may be prepared into tablet, capsule, granule, oral liquid and other forms. It has the functions of benefiting heart, invigorating vital energy, dispersing blood clots and relieving pain; and is used in treating angina pectoris, EKG, chest stuffiness, heart palpitation, etc. It has high effective rate and no negative reaction found.
Application Number
申请号		 03105181 Application Date
申请日		 2003.03.06
Title 名称 Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn
Publication Number
公开号		 1432393 Publication Date
公开日		 2003.07.30
Approval Pub. Date Granted Pub. Date 2005.01.05
International Classification 分类号 A61K35/78,A61P9/10
Applicant(s) Name
申请人		 Ling Peixue
Address 地址 250014
Inventor(s) Name 发明人 Ling Peixue, Zhang Ling
Attorney & Agent 代理人
More information 更  多  信  息


 Related patents information
Eye drops comprising liquaemin or potassium heparin and preparing method thereof
Runshu eye drops and making method thereof
Lubricant for human body
Eye drops contg. sodium hyaluronate and preparing method thereof
Ointment contg. low-molecular heparin and its preparing method
Method for detecting bacterial endotoxin content of hyaluronic acid sodium raw material
Medicine for treating oral ulcer, gastric ulcer, burn and scald and traumatic infection and preparing method
Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method
Eye lotion containing hyaluronic acid and hyaluronic salt and method for making same
Transmission system of medicine containing trehalose and hyaluronic acid for eye part and its preparation method
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.